Study AMB107816, Clinical Evaluation of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension (PAH)- An Open-Label Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A -<Classification: Exploratory and Confirmatory Clinical Trial>
Latest Information Update: 28 Aug 2023
Price :
$35 *
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 19 Sep 2014 New trial record